Timing of chemo and immunotherapy for breast cancer
Part of Cancer, Skin clinical trials.
This trial is testing whether the time of day you receive chemotherapy and pembrolizumab (immunotherapy) affects how well they work against triple-negative breast cancer. It's for people who will get these treatments before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between the ages of 18 and 75
- You have stage II or III triple-negative breast cancer (TNBC)
- Your medical team has decided to treat you with chemotherapy and pembrolizumab before surgery
- You are not taking more than 10 mg of prednisolone (or an equivalent steroid) daily
- You are able to understand and agree to the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy and immunotherapy given before surgery for early-stage triple-negative breast cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a less intense chemotherapy regimen (without one of the standard drugs) combined with immunotherapy for people with early-stage triple-negative breast cancer whose tumors have a high level of immune cells (TILs). The goal is to see if this approach is effective while reducing side effects.
This trial tests a combination of chemotherapy and two immunotherapy drugs given before surgery for women and men with triple-negative breast cancer. The goal is to see if this approach helps shrink or eliminate the tumor before surgery.
This trial tests a combination of chemotherapy, the immunotherapy drug pembrolizumab, and low or high-dose radiation before surgery for people with triple-negative breast cancer that has spread to the lymph nodes. The goal is to see if this approach can improve treatment outcomes.
This trial is for people with early triple-negative breast cancer who had a strong response to chemotherapy combined with pembrolizumab before surgery. It aims to find the best way to continue using pembrolizumab after surgery to reduce the risk of cancer coming back.
This trial looks at how the timing of pembrolizumab (an immunotherapy) infusions affects how well it works against triple-negative breast cancer when given before surgery along with chemotherapy. The goal is to learn if giving the infusion at a certain time of day improves treatment results.
Hear when a new Triple Negative Breast Cancer (TNBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.